Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Other Accumulated Expenses (2019 - 2023)

Vaxcyte (PCVX) has 5 years of Other Accumulated Expenses data on record, last reported at $1.9 million in Q4 2023.

  • On a quarterly basis, Other Accumulated Expenses rose 34.66% to $1.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $1.9 million, a 34.66% increase, with the full-year FY2023 number at $1.9 million, up 34.66% from a year prior.
  • Other Accumulated Expenses reached $1.9 million in Q4 2023 per PCVX's latest filing, down from $2.5 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for PCVX hit a ceiling of $5.0 million in Q3 2021 and a floor of $64000.0 in Q4 2019.
  • A 5-year average of $1.8 million and a median of $1.5 million in 2022 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: soared 1267.24% in 2021, then crashed 76.67% in 2022.
  • Tracing PCVX's Other Accumulated Expenses over 5 years: stood at $64000.0 in 2019, then soared by 575.0% to $432000.0 in 2020, then soared by 746.76% to $3.7 million in 2021, then plummeted by 61.43% to $1.4 million in 2022, then soared by 34.66% to $1.9 million in 2023.
  • Business Quant data shows Other Accumulated Expenses for PCVX at $1.9 million in Q4 2023, $2.5 million in Q3 2023, and $1.9 million in Q2 2023.